A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

Inclusion Criteria:

1. Body mass index (BMI) ≥ 27 kilograms per meter square (kg/m^2)

2. Previously diagnosed with moderate-to-severe OSA

3. AHI ≥15 events per hour (/hr) prior to Randomization

4. AOBP SBP of ≥130 and less than or equal to (≤) 160 millimeter of mercury (mmHg) andAOBP diastolic blood pressure (DBP) ≥60 and ≤110 mmHg

5. Participants on CPAP or PAP therapy are eligible provided they are on PAP for ≥4hours per night and for at least 3 months prior to the study enrollment

6. Participants not currently on PAP therapy, and not anticipated to start PAP for theduration of the study

7. Fertile male and female participants of childbearing potential, and their partners,must agree to use protocol-defined methods of highly effective contraception fromthe Screening Visit until 28 days after the last dose of study drug

Exclusion Criteria:

1. Type 2 diabetes mellitus (T2DM) with a glycosylated hemoglobin (HbA1c) greater than (>) 9 percent (%) (>74.9 millimoles per mol [mmol/mol]) at the Screening Visit orhistory of diabetic ketoacidosis in the 6 months prior to the Screening Visit

2. Participants on a glucagon-like peptide-1 (GLP-1) agonist.

3. Any planned surgery for sleep apnea or major ear, nose or throat surgery, includingtonsillectomy and adenoidectomy during trial participation.

4. Have diagnosis of central or mixed sleep apnea with % of mixed or centralapneas/hypopneas ≥50%, or diagnosis of Cheyne Stokes Respiration

5. Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia

6. Use of bilevel positive airway pressure (BiPAP) therapy.

7. History of clinically significant hyponatremia within 1 year prior to Screening

8. eGFR less than (<) 45 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2)at Screening

9. History of clinically relevant medical, behavioral, or psychiatric disorder, otherthan OSA, that is associated with insomnia or excessive sleepiness

10. Diagnosed with Child-Pugh Class C

11. Participants who regularly use caffeine stimulants or participants who are unwillingto reduce intake to 300 mg per day (approximately 3 cups of coffee), 1 week prior toScreening

12. Treatment with MRAs and/or epithelial sodium channel (ENaC) inhibitors within 1month of the Screening Visit

13. Use of supplemental oxygen

14. Women who are pregnant, plan to become pregnant, or are breastfeeding

15. Hospitalization for the treatment of urgent or emergent hypertension within 1 yearprior to Screening

16. Unstable or currently symptomatic cardiovascular disease or hospitalization in the 6months prior to Screening

17. Previously diagnosed, recurrent orthostatic hypotension

18. Current night-shift worker or anticipated to become a night-shift worker for 3 dayscontinuously during the duration of the study

19. Classified as a New York Heart Association (NYHA) Class III or IV at the ScreeningVisit